Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-28 05:04:46 - browse：7689

Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs well with a biotech downturn?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Casey Ross joins us to tell the bombshell story of how the nation’s largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veteran Michael Gilman calls in to offer a behind-the-scenes peek at what it’s like to be a startup CEO in this economic downturn — and which cocktail recipes help make it bearable. We also discuss a pioneering approval for a genome-editing medicine.

For more on what we cover, here’s the UnitedHealth story; here’s more on the CRISPR approval; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Peter Hotez and the public health issue of online harassment
Next article： John Green on his newest strategy for fighting tuberculosis

hotspot

WSS

Q&A: Jennifer Adair on making gene therapy available globally

More tobacco lobbyists active in statehouses

Getting Alzheimer's drug Leqembi to patients can be a challenge

Change Healthcare outage fallout shows need for new oversight

Change Healthcare outage fallout shows need for new oversight

Why scientists need input from humanists on sensitive research

hotspot

Wikipedia

leisure time

Alkermes shareholders re

Medical bills so high, Medicare adding extra digits to claim forms

At least 13 dead in Texas as scorching temps continue

Why rehabilitation engineers need to center patients in their research

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Wildfire smoke exposes gaps in outdoor worker protections

President Biden's budget: Here's what you might have missed

Alkermes shareholders re

Boston's new lab space is opening empty

knowledge

Close Medicare's dangerous gaps in addiction treatment coverage

Steward Health Care Massachusetts hospitals face fiscal disaster

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Why rehabilitation engineers need to center patients in their research

How many hemophilia patients actually want gene therapy?

Ebola: Gilead Sciences antiviral shows promise as new treatment

hotspot

hotspot

hotspot

focus